化合物PJ34 T6197

Product Introduction
Bioactivity


英文名: PJ34

描述: PJ34 是一种PARP1/2的特异性有效抑制剂，IC50分别为 110 nM 和 86 nM。

细胞实验: PJ34 is dissolved in 100% DMSO at 10 mM and then diluted in DMEM without serum[1]. PC12 cell cultured are grown in Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal calf serum, 5% (v/v) horse serum, and a 1% (v/v) penicillin-streptomycin antibiotics mixture. Cells are grown in an atmosphere of 95% air and 5% CO2 at 37°C. For all experiment, cells are seeded at a density of 4×104 cells/well in 96-well culture plates and allowed to attach overnight. For assessment of cell viability, hydrogen peroxide-induced cytotoxicity is quantified by a standard measurement of LDH release with the use of the LDH assay kit. Briefly, 6 h after hydrogen peroxide exposure, 20 μL of medium of each well is collected, and the solution prepared from LDH assay kit is added. After incubation at room temperature for 30 min, the reaction is stopped by addition of 1 N HCl, and absorbance is measured at 450 nm using a microplate reader.

激酶实验: To assess the PARP-1 or PARP-2 inhibitory activity of FR247304, 3-AB, and PJ34, PARP activity is evaluated with minor modifications. PARP enzyme assay is carried out in a final volume of 100 μL consisting of 50 mM Tris-HCl (pH 8.0), 25 mM MgCl2, 1 mM dithiothreitol, 10 μg activated salmon sperm DNA, 0.1 μCi of [adenylate-32P]NAD, 0.2 units of recombinant human PARP for PARP-1 assay or 0.1 units of recombinant mouse PARP-2 for PARP-2 assay, and various concentrations of FR261529 or 3-AB. The reaction mixture is incubated at room temperature (23°C) for 15 min, and the reaction is terminated by adding 200 μL of ice-cold 20% trichloroacetic acid (TCA) and incubated at 4°C for 10 min. The precipitate is transferred onto GF/B filter and washed three times with 10% TCA solution and 70% ethanol. After the filter is dried, the radioactivity is determined by liquid scintillation counting.

体外活性: PJ34通过抑制PARP酶活性，其IC50值为110±1.9 nM。通过LDH测定法评估PJ34与其他PARP抑制剂在PC12细胞中的神经保护性能，比较结果表明，PJ34在从10-7到10-5 M范围内的浓度下，显著并且依赖浓度地减少细胞死亡[1]。

体内活性: To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33% while 10 mg/kg dosing shows reversed effect (17% reduction)[1]. PJ34 (25 mg/kg) reduces the levels of TNF-α mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice[2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 2.95 mg/mL (10 mM)


关键字: Inhibitor | PARP | PJ-34 | inhibit | PJ34 | PJ 34 | poly ADP ribose polymerase

相关产品: IVHD-valtrate | AZD-2461 | Lupiwighteone | Boehmenan | A-966492 | Talazoparib tosylate | Talazoparib | VPC-70063 | Dehydrocorydaline nitrate | PARP1-IN-5 dihydrochloride 

相关库: Anti-Prostate Cancer Compound Library | Anti-Breast Cancer Compound Library | ReFRAME Related Library | Anti-Cancer Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Epigenetics Compound Library | Anti-Pancreatic Cancer Compound Library | NO PAINS Compound Library | Bioactive Compound Library

化合物PJ34 T6197信息由TargetMol中国为您提供，如您想了解更多关于化合物PJ34 T6197报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途